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ABSTRACT 
             The non-steroidal anti-inflammatory drug (NSAID), diclofenac, has been associated with 
a high risk for cardiovascular events in observational studies.  However, majority of studies 
identifying this association were conducted when diclofenac was the only NSAID that could be 
obtained as a combination product (i.e., formulated with misoprostol).  As a result, channelling 
bias might have resulted if prescribers selected the combination of diclofenac/misoprostol 
(Diclo-Miso) in patients with poor health status frequently than other NSAID products. 
            The main purpose of this study was to identify evidence for channelling bias in a cohort 
of patients with coronary heart disease (CHD) prescribed NSAIDs.  
             Three independent, retrospective analyses were carried out using Saskatchewan’s health 
administrative databases. Patients were eligible if they were hospitalized with CHD event 
between January 1, 1994 and December 31, 2008. In the first analysis, a time series was 
conducted to examine trends in the use of NSAIDs following discharge from original 
hospitalization. In the second analysis, multivariate logistic regression models were constructed 
to identify characteristics of patients prescribed with Diclo-Miso in comparison to single-entity 
diclofenac. Finally, a nested case-control study was conducted to examine the risk for recurrent 
myocardial infarction (MI)/ Unstable Angina (UA) or death among patients prescribed with 
Diclo-Miso versus single-entity diclofenac. For each case, up to five controls were matched by 
age and sex. 
            Between 1994 and 2008, NSAIDs were used by 20.1% (3,099/15,393) of patients in the 
year following discharge from their original MI/UA hospitalization. Use of these agents was 
relatively stable until 2004 when the COX-2 selective agent rofecoxib was withdrawn from the 
market. Following this date (i.e., September 30, 2004), the use of Diclo-Miso and single-entity 
diclofenac appeared to follow different trends. However, available patient and disease specific 
factors could not explain diverging utilization trends. Further, no differences were observed in 
the risk of experiencing recurrent MI/UA between patients receiving Diclo-Miso (OR 0.88, 95% 
CI 0.72-1.08, p=0.22) or single-entity diclofenac (OR 0.78, 95% CI 0.60-1.00, p=0.06) versus 
patients not exposed to NSAIDs.  
          Based on the study’s result, channelling bias does not appear to be a major threat to the 
analysis of cardiovascular toxicity of diclofenac products. 
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1. INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of medications used to 
manage pain and inflammation from a variety of causes 
[1]
. Due to their effectiveness, low cost 
and widespread availability, NSAIDs are one of the most commonly used medications in North 
America 
[2,3]
. However, over the past 10 years, mounting evidence suggests these agents increase 
the risk for cardiovascular events 
[1]
. This discovery prompted a withdrawal of several NSAIDs 
from the market and raised serious questions about the safety of the class as a whole 
[4]
. 
 Many uncertainties remain about the mechanism by which NSAIDs increase 
cardiovascular risk. Moreover, it is not clear whether all NSAIDs exert similar risks or if certain 
NSAIDs are especially harmful. One of the biggest barriers to achieving a full understanding of 
NSAID toxicity is the quality of available evidence. A large number of studies on this issue are 
observational 
[5]
 because randomized trials cannot be ethically conducted to investigate toxicity 
as a primary endpoint. As a result, it can be difficult to assess the extent to which bias may have 
contributed to the findings of published reports. 
 The prescription NSAID diclofenac has been frequently linked with a higher risk for 
cardiovascular events in observational studies 
[5]
. These findings have been widely accepted 
because of a plausible theory explaining its increased risk on the basis of greater selectivity for 
subtype 2 of the cyclooxygenase (COX) enzyme. However, an important source of bias exists in 
observational studies examining the cardiovascular risk associated with diclofenac. Diclofenac is 
unique from all other NSAIDs in one very important way; it is the only NSAID that can be 
prescribed as a combination product that is formulated with a gastric protective agent (until 
recently). To our knowledge, published observational studies have not distinguished between the 
single and combination product of diclofenac in their analyses 
[5, 6]
.  
Research questions: 
1) To what extent has the utilization of prescription NSAIDs changed since 2000 among 
patients discharged after a hospitalization for coronary heart disease (CHD)? 
2) Are there differences in the characteristics of patients who are prescribed the combination 
product of diclofenac and misoprostol (Diclo-Miso) compared to those receiving 
diclofenac alone or other single entity NSAID products?  
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3) Is there evidence that patients receiving diclofenac and misoprostol (Diclo-Miso) 
experience more CHD events compared to those receiving single-entity diclofenac? 
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2. LITERATURE REVIEW 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of medications used for 
managing pain and inflammation. In contrast to opioids (e.g. morphine and codeine), NSAIDs 
have minimal central nervous system effect and can be used without concerns for addiction or 
dependence. Consequently, NSAIDs are used in a plethora of clinical conditions and 
musculoskeletal disorders requiring both short and long term relief 
[1]
. Not only have NSAIDs 
been a crucial tool in pain management, they are among some of the most commonly utilized 
therapeutic drugs of any type. In the United States, approximately 5% of all physician visits 
results in a NSAID prescription 
[2]
. Approximately 25% of Canadians are prescribed NSAIDs 
short term and 4% long term (greater than 6 months), 
[3]
 however three NSAIDs (ibuprofen, 
naproxen and aspirin) are available in Canada without prescription so overall usage is likely 
much higher. Patients can self-select these products without receiving advice on the potential 
side effects and necessary precautions required. 
 The fact that NSAIDs are available over the counter does not mean that they are always 
safe. As with most therapeutic drugs, NSAIDs can be associated with serious side effects. 
Numerous pharmaco-epidemiological studies and meta-analyses have documented serious 
hazards associated with NSAIDs, especially cardiovascular (CV) and gastrointestinal 
complications. In recent years however, there has been an increase in the awareness of 
cardiovascular risk associated with NSAIDs especially in patients with established CV disease 
such as myocardial infarction 
[1]
. In fact two NSAIDs, rofecoxib (Vioxx®) and valdecoxib 
(Bextra®) have been withdrawn from the market due to their cardiovascular risk. Also, 
international guidelines are now discouraging utilization of all NSAIDs in patients with an 
established diagnosis of cardiovascular disease 
[4]
. Moreover, published studies suggest the 
NSAIDs remaining on the market may pose different levels of cardiovascular toxicity. One of 
these medications, diclofenac, has frequently been linked to high rates of CV toxicity in 
observational studies 
[5, 6]
. 
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2.1 PHARMACOLOGY OF NSAIDs 
 NSAIDs reduce pain and inflammation by inhibiting the biosynthesis of prostaglandins 
through blockade of the enzyme cyclooxygenase (COX) which exists in two forms: COX 1 and 
COX 2 (figure 2.1) 
[7]
. 
 
 
 
 
 
 
 
Figure 2.1: NSAIDs mechanism of action 
[7]
 
Traditional or non-selective NSAIDs inhibit both COX-1 and COX- 2 enzymes, while the 
newer, selective NSAIDs inhibit only COX 2 (Table 2.1). Physiologically, COX enzymes differ 
in their expressions and roles. COX-1 enzyme is constitutively expressed in most tissues in the 
body. It is involved in the production of prostaglandin which takes part in platelet aggregation, 
gastric cyto-protection and renal blood flow 
[8]
. On the other hand, the COX-2 enzyme is up-
regulated in inflammatory cells upon infection, injury, or activation by inflammatory cytokines. 
Thus it appears to be primarily responsible for producing prostaglandins that are mediators of 
inflammation 
[8]
. Reducing prostaglandins through selective inhibition of the COX-2 enzymes 
results in similar anti-inflammatory, analgesic and anti-pyretic effects achieved with non-
selective COX-2 inhibition 
[7, 8, 9]
. 
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Table 2.1: Non-selective and Selective NSAIDs currently available in Canada  
Non- selective NSAIDs COX-2 Selective NSAIDs 
Aspirin 
Diclofenac 
Etodolac 
Flurbiprofen 
Ibuprofen 
Indomethacin 
Ketoprofen 
Ketorolac  
Meloxicam 
Mefenamic acid 
Naproxen 
Nabumetone 
Oxaprozin 
Piroxicam 
Sulindac 
Tenoxicam 
Tiaprofenic acid 
Tolmetin 
Celecoxib 
Combination non-selective NSAIDs  
Diclofenac and misoprostol (Diclo-Miso)   
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Naproxen and esomeprazole   
Therapeutic Product Directorate - product drug database Health Canada) 
[10]
 
*Note, this product naproxen and esomeprazole was marketed in 2011 and would not be 
included in published studies of NSAID toxicity
 [11]
  
2.2 NSAIDs TOXICITY 
The inhibition of prostaglandin biosynthesis not only reduces pain and inflammation but it 
also contributes to toxicity that arises from NSAID administration. Prostaglandins are involved 
in many biological functions such as the maintenance of electrolyte balance, renal blood flow 
and vasodilation 
[8, 9]
. The most common toxicities that are associated with prostaglandin 
inhibition include, gastrointestinal mucosal damage, alterations in renal blood flow and, 
cardiovascular toxicity 
[8, 9]
. 
Gastrointestinal (GI) toxicity is the most well-known toxicity associated with NSAID use. 
NSAIDs can cause asymptomatic gastric mucosal damage (e.g. erosions), peptic ulcers and 
serious complications such as bleeding and perforation which often require hospitalization and 
can be life-threatening. NSAID use increases an individual’s risk of peptic ulcer disease (PUD) 
approximately 5 - fold and upper GI bleeding approximately 4 - fold 
[12]
. The overall incidence 
of these events ranges from 2% to 4%, with serious ulcer complications occurring at a rate of 1-
2% of active users. As a result, NSAID toxicity is a major public health issue as over 16,500 
deaths related to NSAIDs occur yearly in the United States and approximately 107, 000 
hospitalizations are as a result of NSAID - related ulcer complications 
[13]
. 
 Several strategies have emerged to reduce the gastro-intestinal toxicity of NSAIDs. 
NSAIDs can be co-prescribed with acid suppressing agents such as proton pump inhibitors (PPI) 
or prostaglandin analogues such as misoprostol 
[14]
. In fact, Pfizer Canada marketed the first 
combination tablet containing a NSAID (diclofenac) and a gastro-protective agent (misoprostol) 
under the name Arthrotec® 
[15]
. Also, AstraZeneca Canada released another NSAID combination 
product in 2011 known as Vimovo® comprising of naproxen and esomeprazole, (a gastric acid 
suppressant) 
[11]
. Prescribers who are concerned about the GI toxicity of NSAIDs can prescribe 
Diclo-Miso or Vimovo®, which contain two separate medications. However, Vimovo® is a 
relatively new product 
[11]
 that is not publicly funded in many provinces (including 
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Saskatchewan) 
[16]
, whereas the combination of diclofenac + misoprostol (i.e., Diclo-Miso) has 
been the only available NSAID/gastro-protective combination for almost two decade 
[17]
. 
Notably, diclofenac can still be prescribed as a single-entity medication for patients in whom a 
gastro protective agent is not necessary. Consequently, Diclo-Miso has likely been prescribed to 
select individuals with poor health or concurrent medical conditions where the risk for adverse 
health outcomes of NSAIDs use is a concern. 
The COX-2 selective inhibitors were originally developed to overcome the risk of GI 
toxicity associated with traditional non-selective NSAIDs 
[18]
. Indeed, randomized trials have 
confirmed the risk for GI toxicity is lower for selective than non-selective NSAIDs but not 
abolished completely 
[19]
. For example, Bombardier and colleagues published a randomized 
control trial (RCT) in 2000, the VIGOR study, to quantify the risk for GI toxicity between 
rofecoxib (a selective COX-2 inhibitor) and naproxen (a non-selective COX-2 inhibitor). Among 
low risk patients enrolled in the study, the rate of GI complications was significantly lower with 
rofecoxib (0.6 per100 person-years.) versus naproxen (1.4 per100 person-years.) and the relative 
risk (RR) of patients in the rofecoxib group in comparison to naproxen was 0.5, (95% CI: 0.3-
0.6; P<0.001) 
[19]
. 
In contrast to the favorable effects on GI toxicity, rofecoxib appeared to be associated 
with an increased risk for myocardial infarction and cardiovascular mortality. Although the 
absolute risk for myocardial infarction and cardiovascular death was low at 0.4% and 0.2% 
respectively, the relative risk of placebo-treated patients compared to those receiving rofecoxib 
was significantly lower (RR: 0.2,  95% CI, 0.1 to 0.7) 
[19]
 . Subsequent to this study, another 
clinical trial which was investigating the use of rofecoxib in treating neoplastic polyps in patients 
with colorectal cancer (Adenomatous Polyp Prevention on Vioxx, APPROVE trial) was 
published with similar findings. Serious thrombotic events were more common among those 
receiving rofecoxib compared to placebo [RR: 1.92, 95% CI 1.19-3.11] after 18 months of 
treatment 
[20]
. Following these findings rofecoxib was withdrawn from the market 
[21]
 and the 
safety of other NSAIDs have since been scrutinized heavily. It is now clear that cardiovascular 
toxicity is a potential complication of most NSAIDs and is not just restricted to selective COX-2 
inhibitors 
[2, 5, 22]
. 
 
 8 
 
2.2 NSAIDs AND CARDIOVASCULAR TOXICITY 
  The cardiovascular toxicity associated with NSAIDs has mainly been associated with 
myocardial infarction (MI) and stroke 
[23]
. These findings are of great significance because of the 
highly prevalent use of NSAID medications and because cardiovascular diseases (CVDs) are the 
number one cause of death globally. In 2008, 17.3 million people died from CVDs representing 
30% of all global deaths. Of these, an estimated 7.3 million were attributed to coronary heart 
disease (CHD) and 6.2 million to stroke. It is predicted that by 2030, an estimated 23.3 million 
people will die from CVDs, especially from heart disease and stroke 
[24]
. The problem of CVD is 
equally striking within Canada. It is responsible for 29% of all Canadian deaths and is one of the 
leading causes of hospitalization, accounting for 16.9% of total all-cause hospitalizations 
[25]
. 
 In more than 90% of individuals, the cause of myocardial infarction (MI) is the rupture, 
erosion or fissuring of an unstable atherosclerotic plaque. These plaques are the hallmark of 
CHD when they develop in the coronary arteries. After the plaque ruptures, a clot or thrombus is 
formed at the top of the ruptured plaque triggering a number of events including the release of 
thromboxane A2 (TXA2), platelet adhesion and obstruction of the artery 
[26]
. Ultimately, 
myocardial tissue can die if the obstructed artery is not opened to re-establish blood flow to the 
affected area. The exact factors predisposing atherosclerotic lesions to rupture remain uncertain; 
however the pathogenesis of NSAIDs-induced cardiovascular toxicity may involve these 
pathways and/or the compensatory changes that follow.  
The development of atherosclerosis is very slow. It involves multiple mechanisms including 
endothelial dysfunction, repression and/or induction of a variety of genes, reduced nitric oxide 
synthesis, inflammation, oxidation and muscle cell proliferation. Environmental and biological 
factors also play a role in atherosclerosis development and progression (Table 2.2) 
[26]
.  In fact a 
high number of Canadians exhibit important risk factors such as obesity, hypertension, 
dyslipidemia and diabetes. NSAIDs use among these types of individuals may contribute to a 
greater risk for cardiovascular diseases. 
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Table 2.2: Risk factors for cardiovascular disease [26] 
Chronic disease Miscellaneous 
Obesity Age 
Hypertension Male gender 
Dyslipidemias Tobacco usage 
Diabetes mellitus Lack of physical activity 
 
  The most commonly proposed mechanism of cardiovascular toxicity resulting from 
NSAIDs use is an imbalance between the production of prostacyclin (PGI2), a potent vasodilator, 
and thromboxane A2 (TXA2), a potent vasoconstrictor. COX-1 enzymes play a role in the 
production of TXA2 while COX-2 enzymes produce PGI2 (Figure 2.2) 
[27]
. According to this 
theory, COX-2 selective NSAIDs preferentially inhibit the production of PGI2 but not TXA2 
[28]
; 
thus, lower levels of PGI2 cannot counteract the vasoconstriction caused by TXA2. Further, lower 
levels of PGI2 could be especially problematic among those with CHD, especially if an 
atherosclerotic plaque has ruptured. 
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*COX - Cyclo-oxygenase enzyme 
**PGH 2 – Prostaglandin H2  
Figure 2.2: Vascular effects of prostacyclin and thromboxane A2 
[8, 23]
 
The COX-2 PGI2 theory is plausible and it provides a straight-forward reason for why 
COX-2 inhibitors such as rofecoxib and valdecoxib were removed from the market due to 
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cardiovascular toxicity. However, this theory does not explain several observations from clinical 
research 
[2]
. Most importantly, in certain studies, non-selective NSAIDs have exhibited similar or 
greater risk of CV toxicity compared to COX-2 selective NSAIDs. Diclofenac is an example of a 
non-selective NSAID that has exhibited high CV risk in numerous studies 
[2, 5, 22]
. 
There is a wealth of research examining NSAID use and cardiovascular outcomes. As of 
2011, approximately fifty one (51) observational studies; 30 case control and 21 cohort studies 
have been conducted 
[5]
. In addition, 280 randomized controlled trials of NSAIDs versus placebo 
and 474 randomized trials of a NSAID against another NSAID can be identified 
[22]
. 
Studies examining the safety of NSAIDs mainly focus on five specific agents (Table 2.3). 
Among non-selective NSAIDs, naproxen, ibuprofen and diclofenac have been studied most 
extensively. Similarly, COX-2 inhibitors, rofecoxib and celecoxib have the most available data 
to evaluate 
[2, 5]
. Currently celecoxib is the only COX-2 selective inhibitor marketed in Canada.
 
[29]
 Three non-selective agents, naproxen 
[30]
 , ibuprofen 
[31]
 and aspirin can be purchased without 
a prescription.  
 
Table 2.3: Most and least studied NSAIDs [2, 5] 
Non-selective NSAIDs COX-2 selective NSAIDs 
Most studied Least studied Most studied Least studied 
Aspirin 
Naproxen 
Ibuprofen 
Diclofenac 
Indomethacin 
Piroxicam 
Meloxicam 
Etodolac 
Rofecoxib 
Celecoxib 
Etoricoxib 
Valdecoxib 
Lumiricoxib 
 
The cardiovascular risk for the COX-2 selective NSAID rofecoxib is very consistent 
across published studies. According to meta-analysis of randomized controlled trials (RCT) 
published in 2011, rofecoxib was associated with a significantly high risk of cardiovascular 
events RR 2.12; 95% CI: 1.26-3.56) 
[2]
.
 
In addition, recent meta-analysis of observational studies 
also associate rofecoxib with increased cardiovascular risk, (RR 1.45; 95% CI: 1.33-1.59) 
[5]
. The 
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fact that rofecoxib has a COX-2 selectivity ≥ 90% supports the theory that COX-2 selectivity is a 
contributing factor to an increased cardiovascular risk 
[32]
. 
Celecoxib has not been associated with the same cardiovascular risks as rofecoxib, 
perhaps because the COX-2 selectivity of celecoxib is lower than rofecoxib 
[32]
. However, 
individual trials examining the risk for cardiovascular toxicity with celecoxib have produced 
odds ratios as low as 0.84 (95% CI: 0.67-1.04) 
[34]
 and as high as 2.53 (95% CI: 1.53-4.18) 
[35]
. In 
a meta-analysis published in 2011, a pooled rate ratio from RCTs was calculated to be 1.35 (95% 
CI: 0.71-2.72) for the risk of MI among celecoxib users 
[2]
. A meta-analysis of observational 
studies (i.e., not RCTs) reported a slightly lower risk ratio but the impact remained statistically 
significantly, (RR 1.17; 95% CI: 1.08-1.27) 
[5]
. Thus celecoxib may still confer an increased risk 
of CV events but this has not been confirmed from pooled RCT results. Many unresolved 
questions remain about the mechanisms of cardiovascular toxicity and the possible differences in 
risk between different NSAID medications. 
The majority of non-selective NSAIDs also appear to exhibit varying degrees of 
cardiovascular risk 
[36]
. Ibuprofen and diclofenac have frequently been associated with increased 
risk for cardiovascular toxicity while risks appear lower with naproxen 
[37]
. Among other 
NSAIDs, estimates of cardiovascular risk are likely unreliable because meta-analyses tend to 
overestimate risk for drugs with limited studies available 
[5]
. 
Naproxen appears to be associated with the least cardiovascular harm 
[2]
. Watson and 
colleagues found a non-significantly lower risk of MI among individuals receiving naproxen 
compared to no NSAID use (OR 0.57; 95% CI: 0.31 – 1.06) [38]. Also, a meta-analysis of RCTs 
found no increased risk of myocardial infarction (MI) or death with naproxen use compared to 
other NSAIDs (RR 0.93; 95% CI: 0.69 – 1.27) [22]. Naproxen’s safety may be linked to its ability 
to suppress platelet COX-1; naproxen exhibits a long half-life (> 12 hrs.) resulting in continued 
and complete suppression of platelet derived COX-1 enzymes. Indeed, it has shown the ability to 
inhibit ≥ 95% of COX-1 enzyme activity [32]. 
 Ibuprofen appears to confer a higher cardiovascular risk in comparison to naproxen 
[39]
. 
However, the cardiovascular risk reported for ibuprofen is sometimes conflicting as there are 
studies which report low risk ratios and others reporting higher risk. For example Watson and 
colleagues found that individuals receiving ibuprofen experienced a non-significantly lower risk 
for myocardial infarction (MI) compared to no NSAID use (OR 0.74, 95% CI: 0.35-1.55) 
[38]
.
 
In 
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addition, ibuprofen was associated with a low risk of recurrent MI within 7 days of starting 
therapy (hazard ratio (HR) 1.04; 95% CI: 0.83-1.30) 
[4]
. In contrast, other studies have found that 
ibuprofen has a high risk for coronary death and MI (rate ratio 1.52; 95% CI: 1.25-1.85) 
[37]
. 
Ibuprofen exhibits poor inhibition of COX-2 enzymes at low doses (≤ 1200 mg/d), but higher 
doses (≥ 1200 mg/d) achieve approximately 90% COX-2 inhibition [32]. These contrasting effects 
may explain some of the variability observed in cardiovascular toxicity with ibuprofen. Overall, 
the most recent meta-analysis of RCTs suggests a significantly increased risk of cardiovascular 
events resulting from ibuprofen use (Table 2.4), (OR 2.2; 95%CI: 1.10-4.48)
 [22]
. 
 
Table 2.4: Risk ratios for serious cardiovascular events associated with NSAID use calculated 
from randomized controlled trials (RCT) and observational studies 
[5, 22] 
NSAIDs Serious Cardiovascular Events, RR (95% CI) vs non-
use of NSAIDs 
Observational Study 
meta-analysis (outcome) 
RCT studies meta-analyses 
(outcome) 
McGettigan & Henry, 
2011 (CV events) 
Baigent et al, 2013 (MI or 
CHD) 
Non- selective 
NSAIDs 
Etodolac 1.55 (1.28-1.87) nr* 
Diclofenac 1.40 (1.27-1.55) 1.70 (1.19-2.41) 
Indomethacin  1.30 (1.19-1.41) nr 
Ibuprofen 1.18 (1.11-1.25) 2.2 (1.10-4.48) 
Meloxican 1.20 (1.07-1.33) nr 
Naproxen 1.09 (1.02-1.16) 0.84 (0.52-1.35) 
Piroxicam 1.08 (0.91-1.30) nr 
COX-2 selective 
NSAIDs 
Etoricoxib 2.05 (1.45– 2.88) nr 
Rofecoxib 1.45 (1.33-1.59) 1.76 (1.31-2.37) 
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Celecoxib 1.17 (1.08-1.27 *analysed together 
*nr – not reported 
 Diclofenac, a non-selective COX inhibitor, has frequently been associated with high rates 
of cardiovascular risk. In fact, a recent meta-analysis of published observational studies suggest 
the risk associated with diclofenac use compared with either non-use or remote use (RR 1.40 
95% CI: 1.27-1.55) is similar to rofecoxib (RR 1.45, 95% CI: 1.33-1.59) and higher than both 
ibuprofen (RR 1.18, 95% CI: 1.11-1.25) and naproxen (RR 1.09, 95% CI: 1.02-1.16) 
[5]
.
   
Following this meta-analysis, another observational study has been published with a strong 
association between diclofenac use and the risk for MI (HR 1.57, 95% CI: 1.36-1.83) that was 
similar to the risks associated with rofecoxib (HR 1.45, 95%CI: 1.18-1.79)
 [1]
. 
 
These reports 
have suggested a consistent and profound cardiovascular risk associated diclofenac use, resulting 
in call for its removal from essential medicine lists (EML) in the United States, which is a list 
comprising of medicines that satisfy the priority health care needs of a population 
[1]
.
  
In theory, 
the increased risk associated with diclofenac is mediated by its relative COX-2 selectivity of > 
90% compared to other non-selective NSAIDs 
[32]
. 
In contrast, there have also been reports of diclofenac’s cardiovascular risk being similar 
to that of other non-selective NSAIDs, ibuprofen specifically. For example, Ray and colleagues 
who conducted a study using databases from Tennessee Medicaid, Saskatchewan Health and 
United Kingdom General Practice Research databases (GPRD) on patients who were previously 
hospitalized for MI, revascularization or unstable angina pectoris, found that the risk of MI with 
diclofenac was (RR 1.26, 95% CI: 0.86-1.84) compared to ibuprofen’s 1.23 (95% CI: 0.86 – 
1.75) compared to individuals not exposed to NSAIDs 
[36]
. Roumie et al also reported similar risk 
of cardiovascular events for diclofenac and ibuprofen after investigating the risk of CV events in 
the patients between the ages of 34-95 years in the United States. Diclofenac’s risk was (HR) 
1.01; 95% CI: 0.76 – 1.34 in comparison to ibuprofen 1.02; 95% CI: 0.90 – 1.15 [39]. Finally, a 
meta-analysis of randomized trials reported a similar risk in diclofenac users (RR 1.41, 95% CI: 
1.12-1.78) compared to ibuprofen users (RR 1.44, 95% CI: 0.89- 2.33) 
[22]
. Thus, although 
reports of diclofenac’s toxicity are concerning and consistent with the COX-2 selectivity theory 
of cardiovascular risk, there remains a substantial amount of evidence that is contradictory. 
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Moreover, no information is available to explain why certain studies come to such differing 
conclusions. 
2.3 BIAS IN OBSERVATIONAL STUDIES EXAMINING NSAID TOXICITY 
 Evidence for the cardiovascular risk with NSAIDs is strong 
[1, 2 5, 22]
. However the exact 
mechanism by which they cause cardiovascular toxicity remains uncertain. Similarly, the extent 
to which cardiovascular toxicity differs among various NSAID agents (both COX-2 selective and 
non-selective agents) has yet to be proven. One of the major problems with published studies in 
this area relates to their study design. Much of the information on cardiovascular toxicity with 
NSAIDs comes from non-randomized studies rather than randomized controlled trials (RCT).  
 In non-randomized studies subjects are allocated treatment based on clinical status, risk 
factors, and patient or physician preference. In contrast, randomized studies assign treatments 
irrespective of patient factors. This fundamental difference in treatment allocation introduces a 
high risk of bias into all non-randomized studies 
[40]
. 
Different types of bias exist; however, channelling bias is of great interest with respect to 
studies examining CVD toxicity with NSAIDs. “Channelling occurs when drug therapies with 
similar indications, either self-selected or clinically assigned, are prescribed to groups of patients 
with varying baseline prognoses” [41].  As a result, non-randomized studies comparing the effects 
of different drug therapies may contain bias due to the impact of baseline differences between 
groups.  In the case of diclofenac, it is plausible that the combination product, Diclo-Miso, has 
been traditionally prescribed to individuals with a higher baseline risk for CVD compared to 
those receiving diclofenac alone or other types of NSAIDs as single entity products. If this 
higher baseline risk is not accounted for, cohorts of individuals receiving diclofenac may exhibit 
higher rates of MI and stroke due to the higher baseline risk among patients who have been 
prescribed Diclo-Miso.  Upon examination of studies reporting outcomes with diclofenac users, 
specifically the more recent meta-analysis of observational studies 
[1, 5, 22]
, none have specifically 
commented on whether combination products were specifically excluded (or stratified) in the 
outcome analyses.                                                                                                        
Evidence for channelling bias can be observed when contrasting the findings meta-
analyses of RCTs versus non-randomized (i.e., observational) studies. The estimated risk ratios 
from observational studies examining diclofenac and ibuprofen were 1.40 versus 1.18 
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respectively 
[5]
. However, risk ratios estimated from published RCTs were 1.41 versus 1.44 
respectively 
[22]
. Notwithstanding the wide confidence intervals and lack of comparative data, 
reasons for these inconsistent findings have not been found. Channelling bias has not been 
adequately investigated with respect to the studies examining diclofenac toxicity. 
Summary  
Research on the cardiovascular safety of NSAIDs has exploded since the first signal of 
harm in 2000. Despite the wealth of studies examining this issue and the withdrawal of several 
agents from the marketplace, there still remains significant uncertainty about the mechanism for 
cardiovascular toxicity and the differences in risk between various agents. Diclofenac has been 
associated with a negative cardiovascular profile that has been attributed to its COX-2 
selectivity. However, studies are conflicting and it appears the issue of channelling bias has 
never been explored as a potential source of bias in diclofenac studies showing harm. 
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3. RESEARCH QUESTIONS 
1) To what extent has the utilization of prescription NSAIDs changed since 2000 among 
patients discharged after a hospitalization for coronary heart disease (CHD)? 
2) Are there differences in the characteristics of patients who are prescribed the combination 
product of diclofenac and misoprostol (Diclo-Miso) compared to those receiving 
diclofenac alone or other single entity NSAID products? 
3) Is there evidence that patients receiving diclofenac and misoprostol (Diclo-Miso) 
experience more CHD events compared to those receiving single-entity diclofenac? 
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4. METHODOLOGY 
4.1 DATA SOURCE 
 This research study was carried out using an existing health-administrative dataset 
containing information on a cohort of subjects in Saskatchewan who were discharged following 
a myocardial infarction (MI) or unstable angina (UA) hospitalization between 1994 and 2008. 
The government of Saskatchewan provides universal health insurance to residents and maintains 
health care utilization information dating back to 1975 
[42]
.
 
These data have been used for high 
quality research in the areas of pharmaco-epidemiology, health economics, and other health 
related areas 
[36, 43, 44, 45, 46]
. 
 Health-administrative databases in Saskatchewan contain information on approximately 
99% of the population including children, the elderly and women of childbearing age.  The 
provincial drug benefit program covers 90% of provincial residents, enabling drug use and other 
health care utilization to be studied simultaneously through database linkage. Approximately 
10% of residents are excluded from the provincial drug benefit program including registered 
First Nations, Armed Forces, or federal inmates because they receive benefits from federal 
programs 
[47]
. 
 The prescription drug database captures data on all medications listed in the provincial 
formulary that are dispensed to beneficiaries receiving treatment outside of hospitals.  For each 
recorded dispensation, information is available on the patient, drug, prescriber, date dispensed, 
cost and quantity supplied.  The medical services database records physician claims for payment 
(i.e., fee-for service claims). Physicians that are not compensated on a fee-for-service basis may 
submit shadow claims (or dummy billings) but it is currently unknown whether these claims are 
consistently and uniformly submitted by these physicians across the province.  Every record in 
this database contains information on the patient, the date of service, the type of service, the 
physician, location and diagnosis.  The hospital services database includes information for every 
discharge, transfer, or death occurring while hospitalized as well as day surgeries. Beneficiaries 
that have out of province hospitalizations are also captured. Hospital diagnoses collected before 
March 31, 2001 were coded using the International Classification of Diseases 9
th
 Revision (ICD-
9) and procedures were coded using Canadian Classification of Diagnostic, Therapeutics & 
Surgical Procedures (CCP). Following April 1, 2001, the majority of hospital diagnoses were 
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coded with the updated version of the ICD (ICD-10-CA) while the Canadian Classification of 
Health Interventions (CCI) algorithm used for procedures 
[47]
. 
 The vital statistics database maintains records for every birth, death, stillbirth and 
marriage, while the population registry contains information on all dates of initiation and 
termination of provincial health benefits. The population registry is updated on a daily basis 
[42, 
47]
. 
 Beneficiary status, health services, and prescription drug use recorded in these databases 
can be linked using a unique health service number (HSN) given to eligible residents 
[47]
. 
 
4.2 OBJECTIVE 1 METHOD 
 
Objective 1: Describe changes in utilization of prescription NSAIDs between 1994 and 2008 
among patients discharged after a hospitalization of coronary heart disease (CHD). 
Hypothesis: 
For this objective, data was presented descriptively and no formal hypothesis testing was 
carried out. 
Study design:  
 A retrospective time series analysis examining NSAID use among individuals discharged 
following a hospitalization from coronary heart disease (CHD) between 1994 and 2008.  
Study population: 
 Subjects were eligible for study if they satisfied the following criteria: a) were discharged 
from hospital following a first coronary heart disease (CHD) event between January 1, 1994 and 
December 31, 2007 (using a 5-year washout period); b) maintained continuous beneficiary status 
for at least five years preceding, and one year following the initial hospitalization. CHD event 
was defined as a myocardial infarction (MI) or unstable angina (UA) listed in the primary or 
most responsible position of the hospital discharge abstract [Table 4.1]. 
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Table 4.1: Diagnostic codes used to identify patients discharged for myocardial infarction (MI) 
or unstable angina (UA) 
[48, 49]
 
ICD codes Disease diagnosis 
 Myocardial infarction (MI) Unstable angina (UA) 
ICD-9 410 411 
ICD-10-CA 121-122 120.0 
124.0 & 124.9 
*ICD- International Classification of Diseases 
 
Subjects satisfying these inclusion criteria were followed for a period of one-year 
following hospital discharge from the original CHD event. The primary endpoint was a 
dispensation for a prescription NSAID during this one year period. To evaluate trends in the use 
of NSAIDs over time, subjects were stratified into quarterly intervals according to their original 
discharge date. The use of NSAIDs was also examined for non-selective and COX-2 selective 
NSAIDs independently in addition to examining all NSAIDs combined. To facilitate 
comparisons over time, rates were standardized by age and sex using the 2001 Saskatchewan 
population as the reference. 
Age and sex standardization was carried out using the following procedure. First, specific 
rates of the endpoint in each year were calculated within pre-defined age categories and further 
divided by sex, relative to the total number of eligible patients in the study sample
 [50]
.
 
 Next, 
weighting for each category above were derived from the reference population defined in the 
first quarter (i.e., January to April) of 2001. The age and sex adjusted rate was defined by the 
sum of each standardized category for a given interval.  
The overall study period (i.e., 1994 to 2007) was divided into three distinct periods.  
Period one begins on January 1
st
, 1994 and ends on September 30
st
 1998.  Period one is unique 
because only non-selective NSAIDs were available on Saskatchewan’s drug benefit list during 
this time. Period two begins on October 1
st
, 1998 and ends on September 30
st
, 2004.  During 
period two, COX-2 inhibitors were newly available on the provincial benefit list in addition to 
non-selective NSAIDs.  In period three (October 1
st
, 2004 to December 31
st
, 2007), rofecoxib 
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had been withdrawn from the market suggesting the risks of NSAID use were more widely 
appreciated 
[4]
. 
 
4.3 OBJECTIVE 2 METHOD 
 
OBJECTIVE #2: Identify patient characteristics associated with Diclo-Miso use (diclofenac 
and misoprostol) compared to the use of diclofenac alone or other single entity NSAID 
products. 
Preamble: 
Published observational studies examining cardiovascular toxicity of NSAIDs do not 
distinguish between individuals receiving Diclo-Miso (diclofenac plus misoprostol) versus 
single-entity diclofenac.  
Hypothesis:  
Patients prescribed the combination product Diclo-Miso exhibit higher levels of 
morbidity, arthritis and advanced age compared to patients receiving diclofenac alone or other 
single-entity NSAIDs. 
Study design: 
Retrospective cohort study  
Study population:  
Patients satisfying the inclusion criteria in objective 1 (i.e., MI or UA diagnosis at 
hospital discharge) were restricted to individuals who received a prescription NSAID within one 
year following hospital discharge. All eligible prescription NSAIDs are listed in Table 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
Table 4.2: Eligible prescription NSAID in Saskatchewan between 1994-2007 categorized based 
on single and combination product NSAID 
 
Single entity NSAIDs Combination NSAID 
Non-selective  Selective  
Diclofenac 
Diflunisal 
Etodolac 
Fenoprofen 
Floctafenine 
Flubiprofen 
Ibuprofen 
Indomethacin 
Ketoprofen 
Mefanamic acid 
Meloxicam 
Nabumetone 
Naproxen 
Phenylbutazone 
Prioxicam 
Sulindac 
Tiaprofenic acid 
Tolmetin 
zomepirac 
Celecoxib 
Rofecoxib 
Valdecoxib 
Diclofenac/misoprostol (Diclo-Miso) 
 
 
 
Data analysis: 
 Baseline characteristics of excluded patients (i.e., no NSAID use) were compared with 
those of patients receiving NSAIDs. Independent sample t-tests were used for continuous 
variables and chi-square for discrete variables. Among patients with at least one NSAID 
dispensation in the one-year  follow up period, multivariate logistic regression models were built 
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to identify differences in patient characteristics between patients receiving Diclo-Miso compared 
to single-entity NSAIDs.  
Numerous demographic, clinical, drug, socioeconomic, and health system factors were 
tested. Demographic variables consisted of age, sex, and rural/urban residence.  The Ministry of 
Health supplied an indicator of urban/rural residence based on Statistics Canada’s definition of 
an “urban agglomeration”.  Specifically, individuals with postal codes occurring in an area 
defined as “urban” or “urban agglomeration” were considered to live in an urban setting.  
General comorbidity was assessed using the Deyo comorbidity Score and Chronic Disease 
Score. The Deyo/Charlson comorbidity was calculated at the index date and based on any 
hospital separations in the year before index (i.e., a discharge date within the 365 days before the 
index date) 
[51, 52]
. The Chronic Disease Score is based on the number of prescriptions dispensed 
in the year prior to the index date 
[53]
. 
Specific comorbidity was assessed using diagnoses for rheumatoid arthritis. It was 
hypothesized that specific arthritis diagnoses would be more commonly documented among 
individuals receiving the Diclo/Miso combination product because it may be perceived as safer 
for those receiving long-term therapy. Similarly, any diagnoses for gastrointestinal comorbidities 
or use of gastro-protective medications were identified separately because it was anticipated that 
patients receiving Diclo-Miso would have higher rates of gastrointestinal problems compared to 
those receiving single-entity NSAIDs (Table 4.3).  
Also, the number of unique cardiovascular medication classes filled in the one year prior 
was served as a measure of cardiovascular morbidity, including angiotensin converting enzymes 
(ACE) inhibitors, angiotensin receptor blockers (ARB), beta-blockers, statins, calcium channel 
blockers (CCB), antiplatelets, anticoagulants, anti-arrhythmic agents, and other anti-hypertensive 
agents. Socioeconomic status was measured with income security benefit which is based on 
whether a patient receives benefits through the provincial Government of Saskatchewan Ministry 
of Social Services or the federal Government of Canada at index-date. Seniors and family based 
benefit are the two types of income security benefit utilized in this study. Seniors based benefit is 
characterized by additional assistance provided from the Government of Saskatchewan to senior 
citizens with little or no income excluding Guaranteed Income Supplement (GIS) and Federal 
Old Age security pension. On the other hand, family based benefit is dependent on The 
Government of Saskatchewan providing low-income families with children supplemental 
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financial assistance for necessities such as food and shelter 
[54]
. Health services utilization was 
assessed with the number of physician visits in the year prior to the index date. Finally year of 
discharge was tested as a possible predictor of Diclo-Miso use (Table 4.3). It was anticipated that 
the year of discharge would interact with other variables so all first order interactions with year 
were investigated in the model.  
 
Table 4.3: Potential risk factors and definition  
Potential risk factor Variable type Description 
Gender Binary Male 
Female 
Age Continuous*  
Rural/urban residence Binary Rural 
Urban 
Deyo comorbidity score Continuous*  
Chronic disease score Continuous*  
Presence or absence of 
rheumatoid arthritis (RA) 
Binary Any diagnosis from hospital file or 
physician services within one year 
prior to initial hospitalization 
 
ICD 9 code for RA, 714. 0 or 
equivalent ICD-10/ ICD-10-CA – 
M05-M06 
[55] 
Presence or absence of GI 
bleed gastrointestinal, 
duodenal, peptic or gastro-
jejunal ulcer  
Binary  
 
Any diagnosis within one year prior to 
initial hospitalization 
 
Gastric ulcer with hemorrhage 
ICD-9 code 531.0, 531.2, 531.4, 531.6 
ICD-10 code K25.0, K25.2, K25.4, 
K25.6 
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Gastrointestinal bleed (GI) 
ICD-9 code 578.X 
ICD-10 code K92.2 
 
Duodenal ulcer with hemorrhage 
ICD-9 code 532.0, 532.2, 532.4, 532.6 
ICD-10 code K26.0, K26.2, K26.4, 
K26.6 
 
Peptic ulcer with hemorrhage 
ICD-9 code 533.0, 533.2, 533.4, 533.6 
ICD-10 code K27.0, K27.2, K27.4, 
K27.6 
 
Gastro-jejunal ulcer 
ICD-9 code 534.0, 534.2, 534.4, 534.6 
ICD-10 code K28.0, K28.2, K28.4, 
K28.6 
Gastro-protective medications  Binary Prior use of PPI*, H2-RA** or 
misoprostol within one year prior to 
initial hospitalization 
 
Cardiovascular pill burden Binary One point given for any class of 
cardiovascular medication dispensed 
at least once. 
 
Class of cardiovascular medication: 
ACE
***
 inhibitors, ARBs***, beta-
blockers, statins, CCBs***, 
antiplatelet, anticoagulants, anti-
arrhythmic agents, other anti-
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hypertensive agents  
Year of hospital discharge Continuous*  
Socioeconomic 
   
Binary  Income security benefit defined as 
either senior or family based benefit 
Physician visits Continuous* The number of physician visits within 
one year prior to initial hospitalization 
*Definition to be determined based on observation in data set 
*PPI – proton pump inhibitors;  
**H2-RA- histamine receptor antagonists 
**ACE- angiotensin converting enzymes; ARBs – angiotensin receptor blockers; CCBs- calcium channel blockers 
 
 
For all independent variables listed in table 4.3, contingency tables were constructed with 
the outcome of receiving Diclo-Miso (y=0, 1) described within k levels of the independent 
variables for nominal, ordinal and continuous variables. Each independent variable underwent 
univariate analysis against the primary endpoint of Diclo-Miso use. Variables that had a p-value 
of less than 0.15 became candidates for the multi-variable model. These eligible variables were 
added stepwise into the full model and were retained if they have a p-value of < 0.15. 
For continuous variables, the following steps were taken to ensure their optimal form in 
the final model: A) obtain quartiles of the variable.  B) Create a 4 level categorical variable using 
3 cut-points based on the quartiles. C) Fit the multivariable model and replace the continuous 
variable (age) with the 4-level categorical variable. D) Plot the estimated coefficients (β) versus 
the midpoints of the groups, and plot a coefficient equal to zero at the midpoint of the first 
quartile. The 4 plotted points were connected to help in the interpretation process. The plot was 
visually inspected to ensure the relationship appears parametric
 [56]
. All first order interactions 
were tested. Finally, both crude (model without potential predictors being adjusted for) and 
adjusted models were presented and interpretations made. 
 In sensitivity analyses, all other single entity NSAIDs users were tested against and used 
as reference to Diclo-Miso users.  
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4.4 OBJECTIVE 3 METHOD 
 
OBJECTIVE #3: Determine if the risk of coronary heart disease (CHD) hospitalization is 
higher among patients receiving Diclo-Miso compared to those receiving single-entity 
diclofenac. 
Preamble: 
Multiple observational studies have found significant associations between diclofenac 
and adverse cardiovascular outcomes despite statistical adjustment for measured confounders. 
However, it is possible that unmeasured confounders resulting from channelling bias may have 
contributed to these higher rates of cardiovascular events.  
Hypothesis: 
  Despite controlling for measured confounders available in the administrative dataset, 
Diclo-Miso use would be associated with recurrent coronary heart disease or death compared to 
single-entity diclofenac use. We assumed that all excess risk associated with Diclo-Miso was a 
result of residual bias (i.e., channelling bias) because misoprostol is not known to have 
cardiovascular toxicity. 
Study design: 
A nested case-control design was used to investigate the association between re-current 
MI/UA or death and type of NSAIDs received.   
Study population: 
  Subjects were eligible for inclusion if they satisfied the following criteria: a) were 
discharged from hospital following a first coronary heart disease (CHD) event between January 
1, 1994 and December 31, 2008 (using a 5-year washout period); b) were continuous health 
beneficiaries for at least 5 years preceding the initial hospitalization; and c) survived without 
recurrent hospitalization for at least 3 months following discharge. Health and drug-utilization 
data was collected for a period up to 15 years following the initial CHD discharge date. Subjects 
were followed until the earliest occurrence of recurrent myocardial infarction (MI), unstable 
angina (UA) or death. Subjects not reaching this study endpoint were censored upon termination 
of health benefits or reaching the end of the study period (December 31, 2008). 
 All patients experiencing a recurrent MI /UA or death between 1994 and 2008 were 
defined as cases. Definition of the MI or UA outcome was consistent with the inclusion criteria 
 28 
 
(Table 4.4). The date of this event was called the CASE-INDEX date. Each case was matched to 
5 control patients randomly selected using incident density sampling. Controls were matched on 
age (+/- 5 years), sex, and time since index event (i.e., initial MI/UA event). 
[43]
 Incident density 
sampling was used to identify controls; using this approach, controls can include individuals who 
experience an event (i.e., a case) at a future time 
[43]
.
 
All control subjects were assigned the same 
CASE-INDEX date as their corresponding case. 
Exposure 
Exposure to prescription NSAIDs were compared during the 3 months preceding the 
CASE-INDEX date. All study subjects were categorized into one of seven mutually exclusive 
exposure categories on the basis of their dispensation records during this period: Diclo-Miso use; 
single-entity diclofenac use; naproxen; indomethacin; other non-selective NSAID use; COX-2 
inhibitors use; multiple NSAID use; no NSAID use (reference).  
 
                                                                                            
                                                  
    
 
 
 
 
 
 
  
 
Figure 4.1: Explanation of case-control method
 
 Data analysis:  
 Differences in exposure to NSAIDs prior to the CASE-INDEX date were analyzed 
descriptively and the odds of experiencing a recurrent MI based on specific NSAID exposures 
was estimated using conditional logistic regression models. Models were constructed using the 
same procedure outlined in objective #2; however, the specific variables to be tested in the 
models were slightly different because they were selected to minimize confounding for 
comparing the risk of MI/UA or death between NSAID groups (Table 4.4).  
 
Discharge 
with 1
st
 
MI/UA  
 
 
Control (note – control individuals are eligible to 
serve as controls even if they are cases at later date)  
Original Cohort Follow-up period 
Case (i.e., recurrent MI/UA or death) 
 
 
Exposure 
period 
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Table 4.4: Potential risk factors and description 
Potential risk factor Variable type Description  
Rural/ urban residence Binary Rural 
Urban 
Presence or absence 
Hypertension 
Binary A diagnosis within two years prior to 
index event. 
One inpatient hospital separation OR two 
or more physician claims within two 
years, selected from the first diagnosis 
field with  ICD-9 or ICD-9-CM code of 
401-405 or equivalent  ICD-10-CA code 
of I10-I13 and I15
 [57]
 
Presence or absence of 
diabetes 
Binary A diagnosis within two years prior to 
index event. 
Two or more physician claims OR one 
inpatient hospital separation within two 
years, selected from the first diagnosis 
field with  ICD-9 or ICD-9-CM code of 
250 or equivalent  ICD-10-CA code of 
E10 to E14
 [57]
 
Modified rheumatoid arthritis Binary  A diagnosis within two years prior to 
index event. 
1 hospitalization RA code ever OR 3 
physician diagnosis code (claims) within 
a 2 year period (ICD 9 code - 714. 0 or 
equivalent ICD-10/ ICD-10-CA – M05-
M06) 
[55]
 
Hospitalizations Continuous* The number of hospitalizations within 
one year prior to initial CHD 
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hospitalization 
Deyo comorbidity score Continuous*  
Chronic disease score Continuous*   
Specific Cardiovascular 
medication use 
ACE/ ARBs 
Beta- blockers 
Statins 
Nitroglycerin 
Clopidorgrel  
Binary variable 
for each 
medication 
Prescription filled in exposure period, 3 
months prior to CASE-INDEX date 
Cardiovascular pill burden  Continuous*  One point given for each class of 
medication dispensed at least once 
 
Class of cardiovascular medication: ACE 
**inhibitors, ARBs**, beta-blockers, 
statins, CCBs**, antiplatelet, 
anticoagulants, anti-arrhythmic agents, 
other anti-hypertensive agents 
Socioeconomic Categorical Income security benefit defined as either 
senior or family based benefit 
Physician visits Continuous* The number of physician visits within 
one year prior to initial CHD  
hospitalization 
*Definition to be determined based on observations in data set 
**ACE- angiotensin converting enzymes; ARBs – angiotensin receptor blockers; CCB= calcium channel blockers 
Although a case-control design would not allow for estimates of risk associated with 
matched variables (age, sex, and time of follow-up), the use of these variables is intended to 
reduce confounding in the primary comparison of NSAID exposure; thus, it is not necessary to 
quantify their risk in order to meet the primary objective. The choice of a case-control design 
was based on the assumption that NSAID use is commonly intermittent and not restricted to a 
single agent. Thus, a case-control design examined the specific NSAID exposure immediately 
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preceding the recurrent MI or UA hospitalization. This analytic approach is consistent with the 
theoretical model of NSAID cardiovascular toxicity where local vaso-dilatory and 
anticoagulant/antiplatelet mechanisms are inhibited.  
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5. RESULTS 
5.1 COHORT DESCRIPTION 
  The original cohort provided by the Saskatchewan Ministry of Health contained records 
for 42,360 patients who were discharged from hospital with a coronary heart disease (CHD) 
event and /or a coronary revascularization procedure between 1994 and 2008.  A total of 21,038 
patients were excluded because they received a revascularization procedure in the absence of a 
diagnosis of MI or UA. The remaining 21,322 patients were discharged with a diagnosis of 
myocardial infarction (MI) or unstable angina (UA). From those MI or UA patients, 19,717 
patients made up the “Base Cohort” containing patients with a first hospital discharge diagnosis 
of myocardial infarction (MI) or unstable angina (UA) and continuous beneficiary coverage for 5 
years prior to first MI/UA [Figure 5.1]. 
 Myocardial infarction was identified in 64.7% (12,774 /19,717) of the discharged 
population, and 64.4% (8,230/12,774) were males. The average age was 68 years old (range 18-
87, SD ±11.15) and the majority were 65 years or older (69.7% or 13,761/19,717).  Also more 
than half of the patients in the base cohort resided in rural areas (52%, 10,267/19,717) and 31.1% 
(6,127/19,717) were receiving seniors based benefit. 
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Figure 5.1: Flow diagram illustrating patients in “base cohort” 
 
 
 
 
42,360 patients discharged with 
CHD event and/ or coronary 
revascularization procedure 
19,717 made up the “Base Cohort” 
Excluded 21,038 
patients without a 
diagnosis of MI or UA 
21,322 patients discharged with 
myocardial infarction (MI) or 
unstable angina (UA) 
Excluded 807 patients with 
a history of MI/UA in the 
previous 5 years and 798 
patients with less than 5 
years of continuous 
beneficiary status prior to 
index event  
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5.2 OBJECTIVE 1 RESULTS 
Objective 1: Describe changes in utilization of prescription NSAIDs between 1994 and 2008 
among patients discharged after a hospitalization for coronary heart disease (CHD)  
From the 19,717 patients experiencing their first MI or UA, 15,393 of those beneficiaries 
could be followed for at least one year after discharge [Figure 5.2]. The mean age of this cohort 
was 67 years old (SD ± 11.33), 62% (9,563/15,393) were male and 61.3 % (9,442/15,393) 
received a diagnosis of MI on the index hospitalization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Flow chart showing how patients were included and excluded from the base cohort 
to satisfy objective 1 
 
Overall, 20.1% (3,099/15,393) of patients received at least one NSAID dispensation 
during the 365 days following hospital discharge. Eleven percent (1,737/15,393) received two or 
more NSAID dispensations during the follow-up year and 8.2% (1,274/15,393) received at least 
three. The most commonly dispensed NSAIDs were diclofenac (33.1%, 1,028/3,099), 
indomethacin (16.9%, 526/3,099), naproxen (14.7%, 456/3,099), celecoxib (11.4%, 356/3,099) 
19,717 patients discharged with 
first myocardial infarction (MI) 
or unstable angina (UA), no 
history of MI/UA and continuous 
beneficiary coverage 5 years 
prior to 1
st
 MI/UA 
 
15,393 eligible for analysis 
Excluded 4,324 with ≤ 1 year 
follow-up (780 died and 3,544 
terminated coverage or reached 
study end date)  
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and rofecoxib 8.1% (254/3,099). Other NSAIDs accounted for the remaining 15.4% (479/3,099).  
Among diclofenac users (n=1,028), the use of the single-entity product (n=525) was similar to 
the combination product, Diclo-Miso (n=503), accounting for 16.9% and 16.2% of those with at 
least one NSAID dispensation respectively (Figure 5.3). 
 
 
Figure 5.3: Number of patients prescribed with NSAIDs within 1 year of MI/UA discharge     
Following age and sex standardization, the percentage of patients receiving at least one 
NSAID dispensation in the one-year follow-up period was plotted over time (Figure 5.4). During 
the first period when only non-selective NSAIDs were available, 19.2% of discharged patients 
received at least one NSAID dispensation in the one year follow-up period. In the second period, 
corresponding to the new availability of COX-2 inhibitors, 21.7% received an NSAID. In the 
final period of analysis (October 1
st
, 2004 to December 31
st
, 2007) following rofecoxib’s 
withdrawal from the market, NSAID use was observed in 15.9% of eligible patients. 
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 Figure 5.4: Percentage of patients receiving at least one prescription NSAID within one-year 
following a coronary heart disease hospitalization in Saskatchewan, Canada between 1994 and 
2007 
Individual NSAID agents were also examined to determine if they followed similar 
trends compared to the aggregate analysis. In general, the use of NSAIDs appeared to decline or 
stabilizes over time with the exception of Diclo-Miso (Figure 5.5). The use of Diclo-Miso 
appeared to increase while the use of single-entity diclofenac product did not appear to change 
between these two periods. The impact of calendar year on diclofenac use was examined in 
objective 2. 
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Figure 5.5: Percentage of patients receiving at least one prescription NSAID within one-year 
following a coronary heart disease hospitalization in Saskatchewan, Canada between 1994 and 
2007 
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5.3 OBJECTIVE 2 RESULTS 
Objective 2: Identify patient characteristics associated with Diclo-Miso use compared to 
the use of single-entity diclofenac or other single entity NSAID products. 
 Among the 15,393 patients examined in objective one, 3,099 received at least one 
NSAID dispensation in the one-year follow-up period. Among these patients, 1,084 received at 
least one dispensation of Diclo-Miso or diclofenac. Fifty six patients were excluded due to the 
use of both Diclo-Miso and diclofenac leaving 525 patients receiving single-entity diclofenac 
and 503 receiving Diclo-Miso exclusively (Table 5.6).   
Baseline characteristics of patients receiving either single-entity diclofenac or Diclo-Miso 
differed for chronic disease score (p=0.03), physician visits in prior year (p=0.02), use of 
cardiovascular medications in prior year (p=0.04), and year of hospital discharge (p<0.01). For 
each of these factors, individuals on Diclo-Miso appeared to demonstrate higher levels of 
comorbidity. In addition, Diclo-Miso use appeared to be used more frequently in the final period 
compared to single-entity diclofenac.  
 
Table 5.6: Characteristics of patients prescribed NSAID products (Diclofenac/Misoprostol (i.e., 
Diclo-Miso), single-entity diclofenac, other single-entity NSAIDs) 
Baseline characteristics Diclo-Miso 
(%) 
Single-entity 
Diclofenac 
(%) 
Other 
NSAIDs 
P-values 
Total patients 503 525 2540 -- 
Gender  
         Males, no. (%)       
 
269 (53.5) 
 
312 (59.4) 
 
1485 (58.5) 
 
0.04 
Mean ± SD* age 67 ± 10.96 66 ± 10.40 68 ± 10.93 -- 
Age 65 or older, no. (%) 341 (67.9) 340 (64.8) 1748 (68.8) 0.65 
Rural/ urban residence 
       Rural, no. (%) 
 
302 (60.0) 
 
325 (61.9) 
 
1410 (55.5) 
 
0.06 
Deyo Comorbidity Score 
[51, 52]
 
       0  
       ≥ 1   
 
430 (85.5) 
73 (14.5) 
 
452 (86.1) 
73 (13.9) 
 
2184 (85.9) 
356 (14.0) 
 
0.77 
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Chronic Disease Score 
[53]
 
       ≤3 
       4 - 5 
       6 - 7 
       ≥ 7 
 
106 (21.1) 
120 (23.9) 
116 (23.1) 
161 (32.0) 
 
130 (24.8) 
140 (26.7) 
129 (24.6) 
126 (24.0) 
 
569 (22.4) 
643 (25.3) 
629 (24.8) 
699 (27.5) 
 
0.77 
GI medication use (1 year 
prior to initial CHD 
hospitalization)** 
        No use 
        Any use 
 
 
 
340 (67.6) 
163 (32.4) 
 
 
 
382 (72.8) 
143 (27.2) 
 
 
 
1844 (72.6) 
696 (27.4) 
 
 
 
0.02 
Use of cardiovascular 
medications in prior year to 
initial CHD hospitalization*** 
     < 3 
     3 -4  
     > 4 
 
 
 
214 (42.5) 
220 (43.7) 
69 (13.7) 
 
 
 
240 (45.7) 
239 (45.5) 
46 (8.8) 
 
 
 
1027 (40.4) 
1208 (47.6) 
305 (12.0) 
 
 
 
0.25 
Rheumatoid arthritis diagnosis 
(1 year prior to initial 
hospitalization) 
        RA disease, no. (%) 
 
 
 
12 (2.4) 
 
 
 
8 (1.5) 
 
 
 
58 (0.2) 
 
 
 
0.89 
GI bleed diagnosis (1 year 
prior to initial 
hospitalization)**** 
         GI bleed, no. (%) 
 
 
 
6 (1.2) 
 
 
 
9 (1.7) 
 
 
 
25 (0.1) 
 
 
 
0.67 
Income security benefit 
       No benefit 
      Any benefit (senior or 
family based) 
 
346 (65.9) 
188 (37.4) 
 
 
179 (34.1) 
 
1624 (64.90 
916 (36.1) 
 
0.56 
Year of hospital discharge 
     Before 1999 
     1999 - 2004 
 
282 (56.1) 
132 (26.2) 
 
351 (66.9) 
136 (25.9) 
 
1080 (42.5) 
1266 (49.8) 
 
<0.0001  
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     After 2004 89 (17.7) 38 (7.2) 194 (7.6) 
Health Services 
Number of physician visits (1 
year prior to initial (1 year 
prior to initial hospitalization) 
     < 10  
     ≥ 10 
 
 
 
 
140 (27.8) 
363 (72.2) 
 
 
 
 
180 (34.3) 
345 (65.7) 
 
 
 
 
880 (34.6) 
1660 (65.3) 
 
 
 
 
0.003 
*SD= standard deviation; 
**GI meds= gastrointestinal medication (proton pump inhibitors, H2 antagonists or misoprostol);  
***Cardiovascular medications ( angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
(ARBs), Beta blockers, statins, calcium channel blockers (CCBs), anti-platelets, anti-coagulants, anti-arrhythmic 
agents and other anti-hypertensive agents);  
****GI bleed= gastrointestinal bleed 
During the model building process where Diclo-Miso was the dependent variable, 
rheumatoid arthritis and GI bleed diagnoses were excluded because of insufficient numbers of 
patients with these diagnoses. All other variables except rural-urban residence, Deyo 
comorbidity score, and income security benefit satisfied the requirement of p-value (p=<0.15). 
The final model contained gender, age, year of hospital discharge and the interaction term year 
of hospital discharge versus age group. 
Year of hospital discharge was the only significant variable in the multivariate model, 
(Table 5.7).  Also within the final model, there was a significant interaction between the terms 
age and year of hospital discharge (p=0.003). However, upon further examination, the interaction 
was not deemed an effect modifier. In other words, the impact of year was consistent within both 
age groups (above and below 65 years). 
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Table 5.7: Crude univariate and multivariate results for potential risk factors in receiving Diclo-
Miso versus diclofenac reporting odds ratio, P-value and 95% CI  
 
Potential risk factors 
 
Crude, univariate 
 
Adjusted, multivariate 
Odds 
ratio 
 95% CI P-value Odds 
ratio 
 95% CI P-value 
Gender 
     Male (ref) 
     Female 
 
1.00 
1.27 
 
 
0.99-1.63 
 
 
0.05 
 
1.00 
1.21 
 
 
0.95-1.57 
 
 
0.13 
Age (categorical) 
    < 65 (ref) 
   ≥ 65     
 
1.00 
1.15 
 
 
0.88-1.48 
 
 
0.30 
 
1.00 
1.23 
 
 
0.95-1.63 
 
 
0.12 
Year of hospital discharge 
     Before1999 (ref) 
     1999 - 2004 
     After 2004 
 
1.00 
1.44 
3.16 
 
 
1.09-1.89 
2.08-4.78 
 
 
0.01 
<0.001 
 
1.00 
1.50 
3.25 
 
 
1.14-1.98 
2.14- 4.94 
 
 
0.004 
<0.001 
Interaction terms 
 
Age ≥65 * Year of hospital 
discharge (1999 -2004) 
 
Age ≥65 * Year of hospital 
discharge (after 2004) 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
2.23 
 
 
0.72 
 
 
1.43-3.47 
 
 
0.33-1.58 
 
 
0.003 
 
 
0.60 
 
Variables not included in the multivariable model 
 
Rural/urban residence 
     Rural (ref) 
     Urban 
 
1.00 
1.08 
 
 
0.84-1.40 
 
 
0.54 
 
 
- 
 
 
- 
 
 
- 
Chronic Disease Score       
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Categorical   
       ≤3 (ref) 
       4 - 5 
6 – 7 
≥7 
 
1.00 
1.05 
1.10 
1.56 
 
 
0.73-1.49 
0.77-1.57 
1.10-2.21 
 
 
0.78 
0.59 
0.01 
 
- 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
Deyo Comorbidity Score  
 0 (ref) 
 ≥ 1 
 
1.00 
1.05 
 
 
0.74-1.50 
 
 
0.78 
 
 
- 
 
 
- 
 
 
- 
GI meds (1 year prior to 
initial CHD hospitalization)* 
 
1.28 
 
0.97-1.67 
 
0.07 
- - - 
CV meds (1 year prior to 
initial CHD hospitalization) 
** 
     < 3 (ref) 
     3 -4  
     > 4 
 
 
 
1.00 
1.03 
1.68 
 
 
 
 
0.79-1.33 
1.11-2.55 
 
 
 
 
0.81 
0.01 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
Income security benefit 
    none (ref) 
   Any benefit (senior or 
family based) 
 
1.00 
1.15 
 
 
 
0.89-1.49 
 
 
0.27 
 
 
 
- 
 
 
- 
 
 
- 
Number of physician visits (1 
year prior to initial CHD 
hospitalization) 
     < 10  
     ≥ 10 
 
 
 
1.00 
1.35 
 
 
 
 
1.04-1.76 
 
 
 
 
0.03 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
 
- 
*GI meds= gastrointestinal medication (proton pump inhibitors, H2 antagonists or misoprostol);  
**CV meds = Cardiovascular medications ( angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs), Beta blockers, statins, calcium channel blockers (CCBs), anti-platelets, anti-coagulants, anti-
arrhythmic agents and other anti-hypertensive agents);  
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Predictors of Diclo-Miso use were re-examined using the same procedures among a 
larger cohort including the use of any single-entity NSAID versus Diclo-Miso (Table 5.8). The 
variables that had <0.15 and thus considered as components of the final model were gender, age, 
rural/urban residence, year of hospital discharge and physician visits (Table 5.8). All the 
variables were significant with a p-value of <0.05 except age and physician visits. Therefore a 
person’s gender, place of residence and year of hospital discharge might be predicting factors in 
being prescribed with Diclo-Miso versus single-entity NSAIDs.  
In testing for interaction terms, there was a significant difference recorded between the 
terms year of hospital discharge and age group (Table 5.8).  There was also a significant between 
Year of hospital discharge and rural/urban residence (Table 5.8). These interaction terms 
however were not considered an effect modifier.  
 
Table 5.8: Crude univariate and multivariate results for potential risk factors in receiving Diclo-
Miso versus any single-entity NSAIDs reporting odds ratio, P-value and 95% CI  
 
Potential risk factors 
 
Crude, univariate 
 
Adjusted, multivariate 
Odds 
ratio 
95% CI P-
value 
Odds 
ratio 
95% CI P-
value 
Gender 
     Male (ref) 
     Female 
 
1.00 
1.22 
 
 
1.01-1.48 
 
 
0.04 
 
1.00 
1.25 
 
 
1.03-1.53 
 
 
0.02 
Age (categorical) 
   < 65 (ref) 
   ≥ 65    
 
1.00 
0.95 
 
 
0.77-1.17 
 
 
0.65 
 
1.00 
0.92 
 
 
0.74-1.14 
 
 
0.44 
Rural/urban residence 
     Rural (ref) 
     Urban 
 
1.00 
0.83 
 
 
0.68-1.01 
 
 
0.06 
 
1.00 
1.25 
 
 
1.02-1.52 
 
 
0.03 
Year of hospital discharge 
     Before1999 (ref) 
     1999 - 2004 
 
1.00 
0.62 
 
 
0.50-0.76 
 
 
<0.00
 
1.00 
0.59 
 
 
0.48-0.74 
 
 
<0.00
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     After 2004 
 
2.06 1.55-2.75 1 
<0.00
1 
1.98 1.48-2.64 1 
<0.00
1 
Number of physician visits (1 
year prior to initial CHD 
hospitalization) 
     10 (ref) 
      ≥10  
 
 
1.00 
1.37 
 
 
 
1.11-1.69 
 
 
 
0.003 
 
 
1.00 
1.01 
 
 
 
0.99-1.01 
 
 
 
0.12 
Interaction terms 
 
Age ≥65 * Year of hospital 
discharge (1999-2004) 
 
Age ≥65 * Year of hospital 
discharge (after 2004) 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
0.71 
 
 
0.63 
 
 
0.50-1.01 
 
 
0.37-1.05 
 
 
0.01 
 
 
0.02 
  
Rural/urban residence* Year 
of hospital discharge (1999-
2004) 
 
Rural/urban residence * Year 
of hospital discharge (after 
2004) 
 
- 
 
 
 
- 
 
- 
 
 
 
- 
 
- 
 
 
 
- 
 
1.61 
 
 
 
1.39 
 
1.14-2.26 
 
 
 
0.82-2.36 
 
0.04 
 
 
 
0.28 
 
Variables not included in the multivariable model 
 
Chronic Disease Score 
Categorical   
       ≤3 (ref) 
       4 - 5 
       6 - 7 
 
 
1.00 
1.00 
0.99 
 
 
 
0.75-1.33 
0.74-1.32 
 
 
 
0.99 
0.95 
 
 
 
- 
- 
 
 
 
- 
- 
 
 
 
- 
- 
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       ≥ 7 1.24 0.95-1.62 0.12 - - - 
Deyo Comorbidity Score  
    0 (ref) 
    ≥ 1 
 
1.00 
1.04 
 
 
0.79-1.37 
 
 
0.76 
 
- 
- 
 
- 
- 
 
- 
- 
 
GI meds (1 year prior to 
initial CHD hospitalization)* 
 
1.27 
 
1.03-1.56 
 
0.02 
 
- 
 
- 
 
- 
CV meds (1 year prior to 
initial CHD 
hospitalization)**  
     < 3 (ref) 
     3 -4  
    > 4 
 
 
 
1.00 
0.87 
1.08 
 
 
 
 
0.71-1.07 
0.80-1.46 
 
 
 
 
0.19 
0.59 
 
 
 
 
- 
- 
 
 
 
 
- 
- 
 
 
 
 
- 
- 
Income security benefit 
    none (ref) 
   Any benefit (senior or 
family based) 
 
1.00 
1.05 
 
 
 
0.86-1.29 
 
 
0.57 
 
- 
- 
 
- 
- 
 
- 
- 
*GI meds= gastrointestinal medication (proton pump inhibitors, H2 antagonists or misoprostol);  
**CV meds= cardiovascular medications ( angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs), Beta blockers, statins, calcium channel blockers (CCBs), anti-platelets, anti-coagulants, anti-
arrhythmic agents and other anti-hypertensive agents);  
 
5.4 OBJECTIVE 3 RESULTS 
Objective 3: To identify evidence for bias in a non-randomized comparison of Diclo-Miso 
versus single-entity diclofenac using conventional methods. 
From the 19,717 patients making up the base-cohort, 4,174 could not be followed for the 
minimum duration of 90 days due to death (n=1,408), termination of health coverage (n=645), 
and reaching the end of the observation period (n=2,121) (Figure 9). Of the 15,543 patients 
eligible for analysis 62.1% (9,645/15,543) were males and the mean age was 67 years old (SD ± 
11.40). The average length of follow-up was 6.41 years (range: 3 months – 15 years). Almost 
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half of the cohort (i.e., 48%, 7,482/15,543) experienced a recurrent MI/UA event or died during 
the follow-up period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Flow chart of showing how many patients were included and excluded from the 
cohort to satisfy objective  
 
Compared to patients who did not experience an outcome (i.e., recurrent MI/UA or death) 
patients developing MI/UA or death were significantly different for all baseline characteristics in 
with the exception of rural/urban residence and number of hospital visits (Table 5.9) 
 
 
 
 
 
 
 
 
 
19,717 patients discharged with 
first myocardial infarction (MI) or 
unstable angina (UA), no history 
of MI/UA and continuous 
beneficiary coverage 5 years prior 
to 1
st
 MI/UA (i.e., the “base 
cohort”) 
 
Excluded 4,174 patients with 
lack of 90 days follow-up after 
discharge 
1,408 died 
645 termination of health 
coverage 
2,121 reached end of study 
period 
 
15,543 patients with MI/UA and 
survived for 90 days or more 
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Table 5.9: Baseline characteristics of NSAID users 3 months after discharge for 1
st
 MI/UA 
 
 
Baseline characteristics 
Cohort description  
MI/UA or death 
outcome 
  
Satisfied 
inclusion criteria 
but no outcome 
experienced 
P-values 
Total (n) 7,482 8,061 - 
Gender, n (%) 
    Male 
    Female 
 
4,533 (60.6) 
2,949 (39.4) 
 
5,112 (63.4) 
2,949 (36.6) 
 
<0.01 
Age ,mean (SD)* 71 ± 9.1 64± 12.3 - 
Demographics, n (%) 
   Rural 
   Urban 
 
3,848 (51.4) 
3,634 (48.6) 
 
4,113 (51.0) 
3,948 (49.0) 
 
0.62 
Clinical disease, n (%) 
     Hypertension 
      Diabetes 
      Rheumatoid arthritis 
 
136 (1.8) 
178 (2.4) 
13 (0.2) 
 
69 (0.9) 
59 (0.7) 
3 (0.03) 
 
<0.01 
<0.01 
0.01 
Chronic Disease Score 
   ≤ 3 (ref) 
   4 - 5 
   6 - 7 
   ≥  7 
 
1,761 (23.5) 
1,810 (24.2) 
1,809 (24.2) 
2,102 (28.1) 
 
3,016 (37.4) 
2,165 (26.9) 
1,564 (19.4) 
1,316 (16.3) 
 
<0.01 
Deyo comorbidity score 
   0 
   ≥ 1 
 
5,968 (79.8) 
1,514 (20.2) 
 
7,455 (92.5) 
606 (7.5) 
 
<0.01 
Year of hospital discharge 
   Before 1999 
   1999 - 2004 
   After 2004 
 
4,316 (57.7) 
2,792 (37.3) 
372 (5.0) 
 
2,492 (30.9) 
3,722 (46.2) 
1,847 (22.9) 
 
<0.01 
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Number of hospital visits 
(1 year prior after initial 
CHD  hospitalization) 
   <  10  
   ≥ 10 
 
 
 
7,470 (99.8) 
12 (0.2) 
 
 
 
8,055 (99.9) 
6 (0.1) 
 
 
 
0.12 
Number of physician visits 
(1 year prior after initial 
CHD hospitalization) 
   <  10  
   ≥ 10 
 
 
 
2,688 (35.9) 
4,794 (64.1) 
 
 
 
4,211 (52.2) 
3,850 (47.8) 
 
 
 
<0.01 
Income security benefit 
   None (ref) 
   Any benefit (senor or 
family based) 
 
4,437 (59.3) 
3,045 (40.7) 
 
 
6,141 (76.2) 
1,920 (23.8) 
 
<0.01 
*SD=standard deviation 
 
Five controls were matched on age and sex for 99.3% (7,431/7,482) for 7,482 cases and 
at least one control was identified for 99.7% (7,467/7,482) of cases. Therefore, the final 
comparison was undertaken with 7,482 cases and 37,203 controls.  At baseline, cases and 
controls were well matched for most characteristics (Table 5.10). However, cases appeared to 
exhibit a slightly higher level of comorbidity as evidenced by 28.1% (2,102/7,482) having a 
chronic disease score of 7 or greater compared to 17.9% (6,666/37,203) with similar chronic 
(Table 5.10). 
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Table 5.10: Baseline characteristics of NSAID users for cases and controls 3 months after 
discharge for 1
st
 MI/UA 
Baseline characteristics Cases (%) Controls (%) 
Total patients (n) 7,482 37,203 
Gender 
     Male 
     Female 
 
4,533(60.6) 
2,949 (39.4) 
 
22,563 (60.6) 
14,640 (39.4) 
Age, mean (SD)* 70 ± 0.04 70± 0.04 
Demographics 
   Rural 
   Urban 
 
3,848 (51.4) 
3,634 (48.6) 
 
19,399 (52.1) 
17,804 (47.9) 
Clinical disease 
     Hypertension 
      Diabetes 
      Rheumatoid arthritis 
 
136 (2.0) 
178 (2.4) 
13 (0.2) 
 
421 (1.1) 
321 (1.0) 
22 (0.1) 
 
 
Chronic Disease Score 
   ≤ 3 
  3 - 5 
  6 - 7 
  ≥ 7 
 
 
 
1,761 (23.5) 
1,810 (24.2) 
1,809 (24.2) 
2,102 (28.1) 
 
 
 
11,578 (31.1) 
10,561 (28.4) 
8,398 (22.6) 
6,666 (17.9) 
Deyo score 
   0 
   ≥ 1 
 
5,968 (79.8) 
1,514 (20.2) 
 
33,378 (89.7) 
3,825 (10.3) 
Year of hospital discharge 
   Before 1999 
   1999 - 2004 
   After 2004 
 
4,316 (57.7) 
2,794 (37.3) 
372 (4.9) 
 
21,485 (57.8) 
14,057 (37.8) 
1,661 (4.5) 
Number of hospital visits (1   
 50 
 
year prior to initial CHD 
hospitalization) 
   <  10  
   ≥ 10 
 
 
7,470 (99.8) 
12 (0.2) 
 
 
37,170 (99.9) 
33 (0.1) 
Number of physician visits (1 
year prior to initial CHD 
hospitalization) 
  <  10  
   ≥ 10 
 
 
 
2,688 (35.9) 
4,794 (64.1) 
 
 
 
16,725 (44.9) 
20,478 (55.0) 
Drugs taken within 90 days of 
discharge 
   Nitroglycerin 
   ACE/ARB** 
   Beta blockers 
   Statin 
   Clopidogrel 
 
 
6,133 (82.0) 
4,947 (66.1) 
4,628 (61.9) 
2,689 (35.9) 
810 (10.8) 
 
 
14,730 (39.6) 
11,272 (30.3) 
11,614 (31.2) 
6,265 (16.8) 
1,862 (5.0) 
Income security benefit 
   None  
   Any benefit (senor or family 
based) 
 
4,437 (59.3) 
3,045 (40.7) 
 
 
24,350 (65.5) 
12,853 (34.5) 
*SD=standard deviation 
** ACE = angiotensin converting enzyme; ARB= angiotensin receptor blocker 
 
All the variables tested on univariate analysis except rural/urban residence were 
significantly associated with the outcome of recurrent MI/UA or death using a threshold of 
p=<0.15 (Table 5.11).  After multivariable adjustment, neither diclofenac (adjusted OR 0.78, 
95% CI 0.60-1.00, p=0.06) or Diclo-Miso (adjusted OR 0.88, 95% CI 0.72-1.08, p=0.22) were 
significantly associated with an increased risk for death or recurrent MI/UA compared to no 
NSAID use. Further, no significant increase in risk was observed among patients receiving 
Diclo-Miso compared to single-entity diclofenac (adjusted OR 1.11, 95% CI 0.81-1.56, p=0.50). 
In contrast, increased risk for the outcome was observed for patients receiving multiple NSAID 
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(adjusted OR 1.67, 95% CI 1.22-2.29, p=<0.01), patients receiving indomethacin [adjusted OR 
1.34 (1.07-1.67), p=0.01] and naproxen [adjusted OR 1.30 (1.04-1.63), p=0.02], (Table 5.11). 
Estimates for the risk of MI/UA or death were not substantially impacted by multivariate 
adjustment.  
Patients who were prescribed beta blockers and nitroglycerin within 3 months after 
discharge, Chronic Disease Score (CDS), physician visits, and income security benefits were 
significant predictors receiving Diclo-Miso while patients who were prescribed ACE/ARBs 90 
days after discharge showed borderline significance (Table 5.11).  
 
Table 5.11: Potential risk factors for recurrent Myocardial Infarction, Unstable Angina or death 
among NSAID users 
 
 
Potential risk factors 
Crude, univariate Adjusted, multivariate 
Odds 
ratio 
95% CI* P-value Odds 
ratio 
95% CI* P-value 
No use (ref) 
Diclofenac 
Diclo-Miso 
Naproxen 
Indomethacin 
Other non-selective 
COX-2 selective agents 
Multiple uses 
1.00 
0.84 
0.99 
1.36 
1.53 
1.20 
1.06 
1.97 
 
0.64-1.08 
0.81-1.20 
1.09-1.69 
1.23-1.89 
0.96-1.48 
0.93-1.20 
1.45-2.68 
 
0.17 
0.88 
0.01 
0.001 
0.10 
0.38 
0.00 
1.00 
0.78 
0.88 
1.30 
1.34 
1.15 
0.92 
1.67 
 
0.60-1.00 
0.72-1.08 
1.04-1.63 
1.07-1.67 
0.93-1.44 
0.81-1.05 
1.22-2.29 
 
0.06 
0.22 
0.02 
0.01 
0.20 
0.21 
0.002 
Chronic Disease Score 
   ≤ 3 (ref) 
   4 - 5 
   6 - 7 
   ≥7 
 
1.00 
1.14 
1.47 
2.17 
 
 
1.06-1.23 
1.36-1.58 
2.03-2.34 
 
 
0.001 
0.001 
0.001 
 
1.00 
1.09 
1.29 
1.78 
 
 
1.02-1.18 
1.20-1.39 
1.65-1.92 
 
 
0.02 
<0.01 
<0.01 
Number of physician visits 
(1 year prior to initial 
CHD hospitalization) 
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     <  10  
      ≥ 10 
1.00 
1.50 
 
1.42-1.59 
 
0.001 
1.00 
1.22 
 
1.15-1.30 
 
<0.01 
    ACE/ARB** 
     B-blockers 
     Statin 
     Nitroglycerin 
1.06 
0.76 
0.68 
1.92 
01-1.12 
0.72-0.80 
0.64-0.72 
1.82-2.03 
0.02 
0.001 
0.001 
0.001 
1.05 
0.79 
0.67 
1.84 
1.00-1.02 
0.74-0.83 
0.63-0.71 
1.74-1.95 
0.05 
<0.01 
<0.01 
<0.01 
Income security benefit 
   None (ref) 
   Any benefit (senior or 
family based) 
 
1.00 
1.34 
 
 
1.27-1.41 
 
 
0.001 
 
1.00 
1.25 
 
 
1.18-1.32 
 
 
<0.01 
Rural/urban residence 0.97 0.92-1.02 0.25 -- -- -- 
 
*CI= confidence interval 
 **ACE = angiotensin converting enzyme; ARB= angiotensin receptor blocker 
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6. DISCUSSION 
The purpose of this study was to perform a retrospective analysis of prescription NSAIDs 
used to identify evidence for channelling bias between Diclo-Miso and diclofenac products.  
Between 1994 and 2004, the utilization of all NSAIDs remained relatively stable among patients 
who had been hospitalized with cardiac event in Saskatchewan. However, following the removal 
of rofecoxib from the market in 2004 (due to concerns over cardiac toxicity), the utilization of 
Diclo-Miso appeared to increase while single-entity diclofenac and other NSAIDs remained 
stable or decreased. This difference in utilization may have been a result of channelling bias in 
that Diclo-Miso and single-entity diclofenac were prescribed to different types of patients. 
Evidence for a unique prescribing pattern of Diclo-Miso following 2004 was confirmed using 
multivariate regression models; year of discharge was strongly associated with the odds of 
receiving Diclo-Miso compared to single-entity diclofenac. However, no significant associations 
were observed with any of the other patient characteristics examined. In addition, the risk of 
death or recurrent cardiovascular morbidity did not differ between Diclo-Miso and single-entity 
diclofenac using conventional methods to control for channelling bias and confounding. Based 
on these results overall, evidence for channelling bias with respect to the integration of Diclo-
Miso and single-entity diclofenac could not be confirmed. 
The overall use of NSAIDs among cardiac patients was not drastically impacted by the 
emergence of COX-2 selective agents on the Saskatchewan market. This low impact may have 
been a result of restrictions associated with their use. Provincial drug coverage for COX-2 
selective agents was restricted to patients with a history of ulcers, age 65 or older, concurrent 
prednisone or warfarin therapy or intolerance to other NSAIDs 
[58]
. As a result, widespread 
prescribing of COX-2 selective agents may have been discouraged by these coverage 
restrictions. However, individuals could have obtained these medications without provincial 
coverage. In this situation, claims for COX-2 inhibitors would not have been captured by the 
prescription drug plan file. Fortunately, a high percentage of subjects in our study were eligible 
for coverage based on age (i.e., ≥65 years); thus, it is expected that this limitation of the data 
source did not drastically influence our results. 
Diclo-Miso use increased following the withdrawal of rofecoxib from the market. This 
trend was the first possible indicator of potential channelling bias in our study. In the absence of 
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bias, Diclo-Miso would have been expected to follow similar utilization pattern as the other 
single-entity NSAIDs, especially diclofenac. If bias was present, it was hypothesized that 
patients receiving Diclo-Miso would be older and exhibit higher levels of comorbidity. However, 
the result of this study failed to indicate a clear preference for Diclo-Miso among patients with 
increased levels of comorbidity or advanced age. Although some variables representing 
comorbidity were associated with Diclo-Miso use in the univariate analyses, none of these 
associations persisted after multivariate adjustment.  
 A comparison of health outcomes between individuals receiving Diclo-Miso versus 
single-entity diclofenac also failed to reveal evidence for channelling bias. It was hypothesized 
that patients receiving Diclo-Miso would exhibit higher rates of recurrent MI/UA and death due 
to channelling bias. In the absence of bias, no differences in health outcomes were expected 
because misoprostol (i.e., the gastro-protective agent (i.e., found in Diclo-Miso) has no known 
impact on cardiac toxicity at prescribed doses 
[59]
. However, the risk for MI/UA or death was not 
statistically different between patients taking Diclo-Miso versus single-entity diclofenac. This 
result corresponded to the findings of objective #2 which failed to identify significant differences 
in patient characteristics between cohorts exposed to these diclofenac products.  
Evidence for channelling bias has been identified previously in utilization studies of 
COX-2 inhibitors. Following the approval of these agents in Canada, rates of hospitalization for 
gastrointestinal (GI) bleeding increased significantly despite evidence suggesting COX-2 
selective agents were safer than traditional NSAIDs
 [50]
. It was assumed that higher rates of 
bleeding were a result of channelling these agents to older/sicker patients 
[50]
. A similar study 
suggested channelling bias was responsible for an observed risk of GI bleeding with a non-
selective NSAID meloxicam 
[60]
.  
 The results of this study indicated diclofenac products (of any kind) did not increase the 
risk for cardiac toxicity. The odds of experiencing a recurrent MI/UA or death compared to no 
NSAID use was 0.88 (95% CI 0.72-1.08) for patients receiving Diclo-Miso and 0.78 (95% CI 
0.60-1.00) for patients receiving single-entity diclofenac. In contrast, published meta-analyses 
have reported significant risk with diclofenac based on RCTs (1.41 RR, 95% CI 1.12-1.78, 
p=0.003) 
[22]
 and observational studies (1.40 RR, 95% CI 1.27-1.55, p=<0.0001) 
[5]
. 
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 The exact reasons for these contrasting estimates of harm remain unidentified. One 
possible factor could have been related to the duration of exposure to diclofenac products. Olsen 
and colleagues found that diclofenac had the highest risk (3.26 hazard ratios, 95% CI 2.75-3.86) 
for recurrent MI or death within the first 1-7 days of use 
[4]
. Dose was another factor which was 
not investigated in our study but Gislason and colleagues found that doses <100mg were not 
significantly associated with death (0.89 HR, 95% CI 0.66-1.20, p=0.45) or recurrent MI (1.27 
HR, 0.92-1.76, p=0.15) compared to patients receiving higher doses (i.e., ≥100 mg per day) [27]. 
Although these factors were not specifically examined in our study, diclofenac cohorts were 
directly compared to patients receiving other NSAIDs and it was assumed that the percentage of 
individuals receiving high doses or extended duration of exposure would be similar for all 
classes of NSAID products. Yet, other NSAID medications were associated with higher risks 
compared to diclofenac. As a result, other unidentified factors likely played an important role in 
these contrasting results.   
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7. LIMITATION 
This study was conducted using Saskatchewan health administrative data, which are 
widely recognized for their accuracy and comprehensiveness
 [47]
. However, despite the use of 
these robust databases, several limitations must be acknowledged. First, the results of this study 
may not be generalizable to other populations because the sample was restricted to patients 
experiencing a cardiac event whereas NSAIDs are used by many different types of patients with 
or without chronic conditions. Although the study inclusion criteria would have undoubtedly 
excluded many NSAID users, individuals eligible for this study exhibited coronary heart disease 
(CHD) at baseline, which is a known risk factor for NSAID induced cardiac toxicity. Therefore, 
this study population was considered an ideal model for testing and comparing the 
cardiovascular risks of NSAID medications. It is also possible that Saskatchewan-specific 
prescribing patterns and drug coverage policies may reduce the generalizability of these findings. 
Second, the period of observation (i.e., 1994-2008) included the introduction of COX-2 selective 
NSAIDs and also the withdrawal of rofecoxib from the market. Overall NSAID use was 
negatively impacted by the latter event, which may have confounded the assessment of 
channelling bias between Diclo-Miso and single-entity diclofenac. Third, ibuprofen became 
available without a prescription in 1993, one year prior to the beginning of the study period (i.e., 
in 1994). Although ibuprofen’s availability as an over-the-counter product likely resulted in an 
underestimate of NSAID use overall, it was not expected to confound the specific comparison of 
Diclo-Miso versus single-entity diclofenac. Fourth, it is possible that differences in NSAID 
toxicity may have been confounded by the extent of exposure. It is known that the length of time 
an individual receives an NSAID along with the dose (i.e., high versus low doses) likely impacts 
the risk for cardiac toxicity 
[4, 27]
. However, it was assumed that the percentage of individuals 
receiving high doses and/ or long-term therapy would be similar between all types of NSAIDs 
examined.  
Lastly, one of the major limitations of population-based databases is the lack of clinical 
information available 
[61]
. This limitation may have confounded the assessment of frailty or 
comorbidity. As a result, the risk associated with diclofenac and/or Diclo-Miso may have been 
confounded by differences in the health status of study patients receiving various NSAID 
products. However, a rigorous approach was used to match patients by age, sex, and discharge 
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year and exposure to NSAIDs was identified in the 90 days preceding each study outcome. In 
addition, several confounding variables were accounted for in the final analysis.   
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8. CONCLUSION 
 
 The results of this study indicate that channelling bias has not been an important 
threat to the assessment of cardiac toxicity of NSAIDs using observational studies. Thus, 
diclofenac must still be considered an NSAID with important risks. However, the results 
of this study provided further conflicting information relating to the risks associated with 
the use of diclofenac. Future studies are needed to clarify the reasons for differences in 
estimated risk associated with diclofenac. 
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